Healthcare Industry News: dermal patch
News Release - January 3, 2006
NeurogesX Appoints Jeffrey Tobias, M.D., as Chief Medical OfficerSAN CARLOS, Calif.--(HSMN NewsFeed)--Jan. 3, 2006--NeurogesX, Inc., a privately held specialty pharmaceutical company focused on the development and commercialization of novel treatments for relief of neuropathic pain, today announced that Jeffrey Tobias, M.D., has joined the company as chief medical officer. Dr. Tobias will be responsible for all clinical development activities, including Transacin(TM), NeurogesX's proprietary dermal patch for the treatment of neuropathic pain.
"We are excited to add Jeff to our team at this important juncture as we move Transacin through Phase 3 clinical trials in HIV-associated neuropathy (HIV-AN) and postherpetic neuralgia (PHN) and prepare the clinical data set for submission for European marketing approval next year. His experience encompasses late-stage clinical trial design and analysis in a variety of fields including pain management," said Anthony DiTonno, NeurogesX president and CEO. "Further, we expect to call upon his new product assessment expertise as we evaluate opportunities to expand our product pipeline next year."
"I'm delighted to be working with the talented team at NeurogesX. Transacin is an exciting new approach to the treatment of neuropathic pain and could have an important impact on the quality of life of patients suffering from this devastating problem," said Dr. Tobias.
Dr. Tobias brings more than 15 years experience in domestic and international clinical drug development, regulatory submissions and strategic planning. Most recently, he served for nine years as principal of the Aquila Consulting Group, LLC, where he specialized in clinical development and strategic planning for U.S. and international biotechnology and pharmaceutical companies. Previous to these activities, Dr. Tobias was director, new product discovery at Alza Corporation, where his responsibilities included the development and in-depth evaluation of new product concepts. He also served as director, clinical development at Chiron Corporation, overseeing large, multi-center Phase 3 clinical trials and as director, clinical research at Xoma Corporation.
Dr. Tobias received board-certification in both Internal Medicine and Pulmonary Medicine and completed training in Critical Care Medicine at the University of California, Los Angeles. He received his bachelor's degree and medical degree with honors from the University of Illinois and has been licensed to practice medicine in both California and the United Kingdom.
NeurogesX is a privately held specialty pharmaceutical company focused on the development of novel treatments for the management of neuropathic pain and improving quality of life using advanced neuroscience insights and innovative delivery technologies. The company's initial products are focused on the treatment of chronic pain in the areas of postherpetic neuralgia (PHN), painful HIV-associated sensory neuropathy (HIV-AN) and painful diabetic neuropathy (PDN). Additional information about NeurogesX can be found at www.neurogesx.com.
NeurogesX is a trademark of NeurogesX, Inc. All other trademarks and registered trademarks are those of their respective companies.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.